50 results on '"Furuno, Kenji"'
Search Results
2. Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY)
3. Respiratory viral infections and Kawasaki disease: A molecular epidemiological analysis
4. Evolutionary dynamics of the novel ST22-PT methicillin-resistant Staphylococcus aureus clone co-harbouring Panton–Valentine leucocidin and duplicated toxic shock syndrome toxin 1 genes
5. Catheter-associated urinary tract infection and urinary tract abnormalities in young children: A retrospective study
6. Clinical Usefulness of T-Cell Receptor Vβ Repertoire Analysis for Differentiating Multisystem Inflammatory Syndrome in Japanese Children From Toxic Shock Syndrome and Kawasaki Disease
7. Clinical Usefulness of T-Cell Receptor Vβ Repertoire Analysis for Differentiating Multisystem Inflammatory Syndrome in Japanese Children From Toxic Shock Syndrome and Kawasaki Disease
8. Clinical significance of serum cytokine profiles for differentiating between Kawasaki disease and its mimickers
9. A registry study of Kawasaki disease patients with coronary artery aneurysms (KIDCAR): a report on a multicenter prospective registry study three years after commencement
10. Incidence and risk factors of acute encephalopathy with biphasic seizures in febrile status epilepticus
11. Nationwide surveillance of bacterial pathogens isolated from children conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2017: General overview of pathogenic antimicrobial susceptibility
12. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin
13. Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational study
14. Leucine-rich alpha-2 glycoprotein in the cerebrospinal fluid is a potential inflammatory biomarker for meningitis
15. Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease
16. CD14 down‐modulation as a real‐time biomarker in Kawasaki disease.
17. Analysis of Coronary Arterial Aneurysm Regression in Patients With Kawasaki Disease by Aneurysm Severity: Factors Associated With Regression
18. A registry study of Kawasaki disease patients with coronary artery aneurysms (KIDCAR): a report on a multicenter prospective registry study three years after commencement
19. Severe encephalopathy associated with SARS-CoV-2 Omicron BA.1 variant infection in a neonate
20. A predictive score for detecting vesicoureteral reflux in children with their first Escherichia coli ‐induced urinary tract infection
21. Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results.
22. Appropriate management of Kawasaki disease patients with coronary artery aneurysms: an interim report on a multicentric prospective registry study three years after commencement
23. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
24. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity
25. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity
26. A phase 3, multicenter, single-arm, open-label study to assess the safety, tolerability, and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese participants aged 6–64 years who are considered to be at increased risk of pneumococcal disease and who are naive to pneumococcal vaccines
27. Kawasaki Disease and Vaccination: Prospective Case-Control and Case-Crossover Studies among Infants in Japan
28. The addition and subtraction of treatment for Kawasaki disease
29. An infant with streptococcal uvulitis presenting with airway obstruction
30. Assessment of Pediatric Admissions for Kawasaki Disease or Infectious Disease During the COVID-19 State of Emergency in Japan
31. Revision of diagnostic guidelines for Kawasaki disease (6th revised edition)
32. Drug‐induced hypersensitivity syndrome by i.v. immunoglobulin administration for Kawasaki disease
33. The Impact of the COVID-19 State of Emergency on the Incidence of Kawasaki Disease in Japan: A Multicenter Observational Study
34. Lipidomics links oxidized phosphatidylcholines and coronary arteritis in Kawasaki disease
35. Infantile osteomyelitis of the fourth rib causing the occurrence of a lung abscess
36. Bullous artificial dermatitis due to aerosol sprays masquerading as fixed drug eruption
37. Klebsiella pneumoniae -associated septic pulmonary emboli in a healthy child
38. Macrophages and cytotoxic T cells infiltrate the destructed mitral tissue in Kawasaki disease
39. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open‐Label, Randomized Control Study
40. Nasopharyngeal glial heterotopia with delayed postoperative meningitis
41. Bilateral hydronephrosis due to obstructive ureteral stone associated with norovirus gastroenteritis
42. Bacteriological Analysis of Pneumococcus Detected from the Sputum of Hospitalized Children
43. A New Z Score Curve of the Coronary Arterial Internal Diameter Using the Lambda-Mu-Sigma Method in a Pediatric Population
44. Abstract 93: Analysis of Serum Levels of Procalcitonin and Serum Amyloid A as Biomarkers of Intravenous immunoglobulin-resistant Kawasaki Disease
45. Bullous artificial dermatitis due to aerosol sprays masquerading as fixed drug eruption.
46. Association of Severity of Coronary Artery Aneurysms in Patients With Kawasaki Disease and Risk of Later Coronary Events
47. A New ZScore Curve of the Coronary Arterial Internal Diameter Using the Lambda-Mu-Sigma Method in a Pediatric Population
48. Clinical Characteristics of Cryopyrin-Associated Periodic Syndrome and Long-Term Real-World Efficacy and Tolerability of Canakinumab in Japan: Results of a Nationwide Survey.
49. CD14 down-modulation as a real-time biomarker in Kawasaki disease.
50. Lipidomics links oxidized phosphatidylcholines and coronary arteritis in Kawasaki disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.